Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Opioid substitution treatment principles

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Do not dose through opioid toxicity

Drowsiness, slurred speech, ataxia, pinpoint pupils or reduced respiratory rate before a planned methadone or buprenorphine dose suggests intoxication or dangerous sedative co-use; methadone accumulation is particularly hazardous during induction.

Action: Withhold the dose pending urgent clinical assessment, support airway and breathing, use naloxone for respiratory depression, and verify recent prescribed and non-prescribed opioids, alcohol, benzodiazepines and gabapentinoids. Restart or adjust only through the responsible specialist prescriber after intoxication, tolerance and missed doses are reviewed.

Overview

Use methadone or buprenorphine safely and collaboratively to reduce illicit opioid use, overdose and treatment dropout, with evidence-based induction, therapeutic dosing, supervision, monitoring, naloxone and continuity across care settings.

Opioid substitution treatment replaces unpredictable short-acting illicit opioids with a pharmaceutical opioid of known strength and longer action. The aims are to stop withdrawal and craving, reduce or stop non-prescribed use, prevent overdose and infection, improve stability and keep the person engaged with health and social care. Abstinence may be a future goal for some, but arbitrary dose reduction or discharge for ongoing use can increase mortality. Assess goals, tolerance, current drugs and route, overdose history, withdrawal, physical and mental health, pregnancy, housing, safeguarding and previous treatment before prescribing.

Methadone is a full mu-opioid agonist with strong treatment retention but a long and variable half-life. Repeated daily doses can accumulate before steady state, so induction carries disproportionate overdose risk. Buprenorphine is a high-affinity partial agonist with a ceiling on respiratory depression and generally lower overdose risk, although sedative combinations remain potentially fatal. Its high receptor affinity can displace a full agonist and precipitate withdrawal if started too early. Choice should reflect patient preference, tolerance, sedative use, cardiac and respiratory disease, prior response, supervision access and diversion risk.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Choosing safer substitution treatment

A man with opioid dependence has uncertain current tolerance, severe chronic lung disease and intermittent non-prescribed benzodiazepine use. Which medication preference best matches current DHSC guidance?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • DHSC oral methadone and buprenorphine recommendationsCurrent choice, rapid access, buprenorphine induction, therapeutic dose and supervision principles.
  • DHSC drug misuse and dependence UK clinical guidelinesOrange Book induction, monitoring, psychosocial care and harm reduction.
  • NICE TA114 methadone and buprenorphine guidanceBoth medicines as options within a programme of support.
  • NICE CG52 opioid detoxification recommendationsAssessment, first-line medicines, testing and care settings.
  • Methadone 1 mg per ml oral solution SmPCProduct-specific start, titration, accumulation and safety information.
  • Buprenorphine 8 mg sublingual tablet SmPCPrecipitated withdrawal and sedative-combination warnings.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

The 2024 DHSC supplement says appropriate patients should have rapid prescribing access, including on the first day of service, while maintaining adequate assessment. Both methadone and buprenorphine should be available. It recommends buprenorphine preferentially for low or uncertain tolerance, concerning sedative exposure, significant cardiac or respiratory disease and some access barriers. Methadone may still be appropriate after an individualized risk-benefit assessment. Biological testing and physical examination are usually completed before treatment, but administrative rigidity should not create unnecessary delay.

Dose for effectiveness as well as safety. Under-dosing leaves withdrawal and drives continued illicit use; overly rapid induction causes intoxication. Current national evidence ranges are methadone 60–120 mg daily and buprenorphine 8–16 mg daily, up to 32 mg, but response is individual. For buprenorphine induction, most adults need an adequate 4–8 mg first-day dose once significant objective withdrawal is present, with review the next day and an increase of up to another 8 mg if required. Methadone begins lower and increases cautiously because today’s dose adds to residual drug from previous days.

Supervision and take-away arrangements are clinical decisions, not punishment. Methadone consumption is usually supervised initially until stable. Buprenorphine may be supplied unsupervised from the start, sometimes up to seven days, when individual assessment supports this, while instability or diversion may justify renewed supervision. At every stage provide naloxone, discuss alcohol and sedative risk, secure storage away from children, safer injecting and blood-borne-virus care. Prescribing must transfer smoothly across admission, discharge, relocation and prison release, with dose verified from the dispensing source rather than guessed.

Key points

  • Opioid substitution treatment is usually long-term treatment, not simply a bridge to detoxification; retention itself reduces exposure to illicit supply and mortality risk.
  • Current DHSC guidance requires both oral methadone and buprenorphine to be available and usually offered as a shared choice with risks and benefits explained.
  • Prefer buprenorphine when tolerance is low or uncertain, sedative use is concerning, important cardiac or respiratory disease exists, or supervised consumption is not feasible, while individual exceptions remain possible.
  • Start buprenorphine only when objective opioid withdrawal is present to avoid precipitated withdrawal; current national guidance supports 4–8 mg on day 1 for most adults and reassessment the next day for up to a further 8 mg if required.
  • Evidence-based therapeutic ranges are commonly methadone 60–120 mg once daily and buprenorphine 8–16 mg once daily, up to 32 mg, but the correct dose is the individual dose that suppresses withdrawal and non-prescribed opioid use without intoxication.
  • A current methadone 1 mg/mL SmPC gives an initial oral dose of 10–20 mg once daily with cautious 10–20 mg daily increases; accumulation means every increment requires assessment and this product schedule is not automatic.
  • Methadone supervision is usual at treatment start until stability; current guidance allows individualized early take-away or unsupervised buprenorphine when assessed benefits outweigh diversion and safety risks.

Aetiology

01

Opioid neuroadaptation

Repeated receptor activation produces tolerance and a withdrawal state that reinforces continued use and rapid relief seeking.

02

Unregulated supply

Variable purity, potent synthetic opioids and contamination expose people to unpredictable doses that a known pharmaceutical medicine can replace.

03

Structural vulnerability

Trauma, pain, homelessness, poverty, imprisonment, stigma and fragmented services can sustain risky use and interrupt otherwise effective treatment.

Pathophysiology

  1. 1
    Full agonist substitution

    Methadone provides sustained mu-receptor activation, preventing withdrawal without the rapid concentration peaks of short-acting illicit opioids.

  2. 2
    Partial agonist occupancy

    Buprenorphine binds receptors strongly but activates them partially, suppressing withdrawal with a ceiling effect on respiratory depression.

  3. 3
    Delayed accumulation

    Methadone's long variable elimination means successive daily doses can raise exposure for several days after an increase.

  4. 4
    Receptor displacement

    Buprenorphine can displace a full agonist while providing less activation, producing abrupt withdrawal if induction precedes adequate spontaneous withdrawal.

Clinical features and red flags

Adequate stabilisation

Withdrawal and craving remain controlled through twenty-four hours, non-prescribed opioid use falls and the patient stays alert and functional.

Underdosing

Persistent early-morning withdrawal, craving or continued illicit opioid use may indicate inadequate dose, missed consumption or another unmet need.

Opioid intoxication

Drowsiness, slurred speech, ataxia, constricted pupils and respiratory slowing require dose withholding and urgent clinical review.

Precipitated withdrawal

An abrupt severe syndrome shortly after buprenorphine indicates that a full agonist was still occupying receptors at induction.

Diversion or coercion risk

Lost doses, irregular pickup, pressure from others, unsafe storage or unexpected tests require collaborative reassessment of dispensing arrangements.

Red flags requiring action

  • Sedation, respiratory slowing or intoxication before observed consumption requires the dose to be withheld and urgently assessed rather than automatically administered.
  • Uncertain or low opioid tolerance, recent abstinence, missed doses or prison or hospital transition substantially increases induction and restart risk.
  • Concurrent alcohol, benzodiazepine, gabapentinoid or other sedative use raises fatal oversedation risk with both methadone and buprenorphine.

Investigations

  1. 01
    Comprehensive opioid assessmentFirst step
    Why
    Establish dependence, tolerance, current supply, route, last use, overdose and previous treatment.
    Interpretation and limitations
    Dose and medicine choice depend on observed clinical tolerance and corroboration, not a reported street quantity alone.
  2. 02
    Physical and mental state examination
    Why
    Identify intoxication, objective withdrawal, injection complications, respiratory disease, pregnancy and acute psychiatric risk.
    Interpretation and limitations
    Do not give an induction dose through sedation; objective withdrawal is needed before conventional buprenorphine initiation.
  3. 03
    Biological drug testing
    Why
    Support the history and detect relevant opioids and sedatives before and during treatment.
    Interpretation and limitations
    A result is one part of assessment, varies by assay and detection window, and should guide care rather than automatic exclusion.
  4. 04
    Electrocardiogram when indicated
    Why
    Evaluate QT risk with methadone in people with cardiac disease, syncope, high dose, interacting drugs or electrolyte disturbance.
    Interpretation and limitations
    An important QT abnormality prompts correction of reversible factors and specialist review of dose or medicine choice.

Differential diagnosis

01

Pain-driven opioid use

Poorly controlled acute or chronic pain may coexist with dependence and needs a coordinated analgesia plan rather than moral interpretation.

02

Non-dependent intermittent use

Occasional exposure carries overdose risk but may not produce tolerance or withdrawal sufficient to justify the same induction dose.

03

Sedative intoxication

Alcohol, benzodiazepines and gabapentinoids can account for drowsiness before dosing and amplify either substitution medicine's respiratory effect.

04

Primary gastrointestinal illness

Infection, inflammatory disease and medication effects can resemble withdrawal diarrhoea, vomiting and cramps, especially without objective autonomic signs.

Management

01ChoiceSelect medicine collaborativelyFirst stepOpioid dependence is established and substitution treatment is clinically appropriate.+
  1. 1Discuss methadone and buprenorphine effects, induction, supervision, interactions, prior experience and the person's goals.
  2. 2Prefer buprenorphine where low tolerance, sedatives, cardiac or respiratory disease or supervision barriers make its safety profile advantageous.
  3. 3Agree a rapid but adequately assessed start, naloxone supply, pharmacy arrangement and clear contact route for early problems.
02InductionStart without creating toxicityThe medicine and initial dispensing plan have been selected.+
  1. 1For methadone, verify tolerance, start with the product and specialist protocol dose and reassess before every cautious increase because accumulation is delayed.
  2. 2

Complications

01

Induction overdose

Excess methadone accumulation or dosing through intoxication can cause delayed respiratory depression and death early in treatment.

02

Precipitated withdrawal

Premature buprenorphine induction can cause an abrupt severe syndrome that threatens engagement and drives return to full agonists.

03

Diversion poisoning

Take-home methadone or buprenorphine can harm opioid-naive adults and children when coerced, shared or stored unsafely.

04

Interrupted treatment

Administrative prescribing gaps provoke withdrawal, return to the illicit market, reduced tolerance and overdose around hospital or custody transitions.

Monitoring and follow-up

  • During induction, review alertness, respiratory state, withdrawal, craving, non-prescribed use and other sedatives before each increment.
  • Confirm pharmacy attendance and random toxicology where agreed, interpreting results in the context of assay limits and treatment goals.
  • Review dose adequacy, functioning, overdose, injection injury, mental health, pain, housing and safeguarding rather than focusing on abstinence alone.
  • Reassess supervision, take-home quantity, secure storage and coercion or diversion whenever household or stability changes.
  • At every admission, discharge or custody transition, verify the last dose and dispensing record and communicate the next authorized dose directly.

Special situations

Retention is protective

Remaining in effective treatment reduces mortality; ongoing non-prescribed use is a reason to optimise care, not automatically to stop medication.

Methadone risk is delayed

A dose that seems tolerated today may accumulate over several days, so early escalation cannot be judged from immediate effect alone.

Buprenorphine needs withdrawal

Observable withdrawal, opioid type and last exposure matter more than a rigid clock time when preventing precipitated withdrawal.

Supervision is individualized

Current guidance moves away from a universal duration and balances diversion risk against treatment access, dignity and dropout.

Verify every transition

A guessed dose can intoxicate a person whose tolerance has fallen, while an avoidable interruption can drive withdrawal and illicit use.

Common pitfalls

  1. 01

    Treating opioid substitution as a short detoxification course regardless of the person's stability and preference.

  2. 02

    Administering methadone or buprenorphine when the patient is already sedated or breathing slowly.

  3. 03

    Starting conventional buprenorphine before objective withdrawal because a fixed number of hours has elapsed.

  4. 04

    Leaving someone chronically underdosed while blaming continued illicit use on motivation alone.

  5. 05

    Applying supervised consumption as punishment or removing it without assessing household and diversion risk.

  6. 06

    Restarting a reported community dose after missed doses or admission without verifying the dispensing record.

Content changes
Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Provide take-home naloxone, safe-storage advice and seamless prescribing across hospital, prison, pharmacy and community services; an administrative gap can be fatal.
    • Syncope, palpitations, major QT prolongation, severe respiratory disease or important hepatic impairment requires specialist medicine review.
  • Pregnancy, acute pain, planned surgery, admission or release from custody needs rapid coordination to avoid an unintended prescription interruption or unsafe withdrawal.
    • 05
    Blood-borne virus and health screen
    Why
    Offer HIV and hepatitis testing, vaccination, liver assessment, pregnancy testing and other care according to exposure and consent.
    Interpretation and limitations
    Results should open prevention and treatment pathways and never be used as a condition for substitution treatment.
    For buprenorphine, wait for significant objective withdrawal, usually give 4–8 mg on day 1, and reassess next day for up to another 8 mg if needed.
  • 3Withhold and urgently review any dose when sedation or slow breathing is present, and revise for missed doses, new sedatives or acute illness.
    • 03MaintenanceOptimise retention and safetyThe patient has begun treatment and needs ongoing dose and dispensing review.+
    1. 1Titrate to a dose that prevents withdrawal and substantially reduces non-prescribed opioid use without causing intoxication.
    2. 2Review supervised or take-away consumption using stability, diversion, household safety and treatment-burden evidence rather than a fixed punitive rule.
    3. 3Maintain naloxone, psychosocial and physical-health care, and arrange verified uninterrupted prescribing through every care transition.
    Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
    A long-acting full agonist suppresses withdrawal and craving and often provides strong retention in opioid-dependence treatment.

    Methadone oral solution

    A current 1 mg/mL product SmPC gives 10–20 mg by mouth once daily initially, with cautious increases of 10–20 mg per day until neither withdrawal nor intoxication is present. National evidence places many effective maintenance doses at 60–120 mg once daily; induction and any increase require specialist assessment and must not be applied as an automatic schedule.

    Accumulation can cause delayed fatal respiratory depression, especially early in treatment, after missed doses or with alcohol, benzodiazepines and gabapentinoids. Check interactions and QT risk, use caution in respiratory or hepatic disease, supervise initially when indicated and store securely away from children.

    A high-affinity partial agonist treats withdrawal and craving with lower induction mortality than methadone and flexible dispensing for suitable patients.

    Buprenorphine sublingual

    When significant objective withdrawal is present, current DHSC guidance supports an adequate 4–8 mg sublingual dose on day 1 for most adults, followed by reassessment the next day and an increase of up to a further 8 mg if required. Typical effective daily dosing is 8–16 mg, individualized up to 32 mg.

    Starting before full-agonist effects have subsided can precipitate severe withdrawal; do not rely on a universal elapsed-time rule. Sedative combinations still cause fatal respiratory depression, tablets can be diverted, hepatic disease needs review and observed sublingual technique may be needed.